Cargando…

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

BACKGROUND: There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. METHODS: EGFR mutated stage IIIB and IV NSCLC patients diagn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gutiérrez, Lourdes, Royuela, Ana, Carcereny, Enric, López-Castro, Rafael, Rodríguez-Abreu, Delvys, Massuti, Bartomeu, González-Larriba, José Luis, García-Campelo, Rosario, Bosch-Barrera, Joaquim, Guirado, María, Camps, Carlos, Dómine, Manuel, Bernabé, Reyes, Casal, Joaquín, Oramas, Juana, Ortega, Ana Laura, Sala, Mª. Angeles, Padilla, Airam, Aguiar, David, Juan-Vidal, Oscar, Blanco, Remei, del Barco, Edel, Martínez-Banaclocha, Natividad, Benítez, Gretel, de Vega, Blanca, Hernández, Ainhoa, Saigi, Maria, Franco, Fernando, Provencio, Mariano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406921/ https://www.ncbi.nlm.nih.gov/pubmed/34465283 http://dx.doi.org/10.1186/s12885-021-08713-8

Ejemplares similares

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics
por: Provencio, Mariano, et al.
Publicado: (2022)

Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry
por: Franco, Fernando, et al.
Publicado: (2021)

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study
por: Provencio, Mariano, et al.
Publicado: (2023)

Are there differences by sex in lung cancer characteristics at diagnosis? —a nationwide study
por: Ruano-Ravina, Alberto, et al.
Publicado: (2021)

Lung cancer symptoms at diagnosis: results of a nationwide registry study
por: Ruano-Raviña, Alberto, et al.
Publicado: (2020)

Prospective Exploratory Analysis of Angiogenic Biomarkers in Peripheral Blood in Advanced NSCLC Patients Treated With Bevacizumab Plus Chemotherapy: The ANGIOMET Study
por: Jantus-Lewintre, Eloisa, et al.
Publicado: (2021)

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)
por: Provencio, Mariano, et al.
Publicado: (2022)

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden: A Nonrandomized Controlled Trial
por: Provencio, Mariano, et al.
Publicado: (2022)

Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)
por: Franco, Fernando, et al.
Publicado: (2021)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2022)

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial
por: Laza‐Briviesca, Raquel, et al.
Publicado: (2021)

Prognostic value of quantitative ctDNA levels in non small cell lung cancer patients
por: Provencio, Mariano, et al.
Publicado: (2017)

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial
por: Sierra-Rodero, Belén, et al.
Publicado: (2021)

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy
por: Casarrubios, Marta, et al.
Publicado: (2021)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
por: Majem, M., et al.
Publicado: (2018)

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
por: Romero, Atocha, et al.
Publicado: (2020)

NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment
por: Sánchez‐Herrero, Estela, et al.
Publicado: (2021)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015
por: García-Campelo, R., et al.
Publicado: (2015)

Increased Glyphosate-Induced Gene Expression in the Shikimate Pathway Is Abolished in the Presence of Aromatic Amino Acids and Mimicked by Shikimate
por: Zulet-González, Ainhoa, et al.
Publicado: (2020)

Small-Cell Lung Cancer Long-Term Survivor Patients: How to Find a Needle in a Haystack?
por: Plaja, Andrea, et al.
Publicado: (2021)

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)
por: Nadal, Ernest, et al.
Publicado: (2023)

Physiological Approach to the Use of the Natural Compound Quinate in the Control of Sensitive and Resistant Papaver rhoeas
por: Zabalza, Ana, et al.
Publicado: (2020)

Assessment of the psychosocial and economic impact according to sex in non-small cell lung cancer patients: an exploratory longitudinal study
por: Viñolas, N. Nuria, et al.
Publicado: (2020)

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
por: Provencio, Mariano, et al.
Publicado: (2022)

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer
por: Simonetti, Sara, et al.
Publicado: (2010)

Neoadjuvant chemoimmunotherapy in resectable stage IIIA/IIIB non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2021)

Ionic liquids IIIB
por: Rogers, Robin D, et al.
Publicado: (2005)

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
por: Garrido, Pilar, et al.
Publicado: (2021)

Characterization of a cohort of metastatic lung cancer patients harboring KRAS mutations treated with immunotherapy: differences according to KRAS G12C vs. non-G12C
por: Notario, Lucía, et al.
Publicado: (2023)

Optical fiber telecommunications IIIB
Publicado: (1997)

SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)
por: Gumà, Josep, et al.
Publicado: (2023)

Correlation between PD-L1 expression and MET gene amplification in patients with advanced non-small cell lung cancer and no other actionable oncogenic driver
por: Domènech, Marta, et al.
Publicado: (2021)

Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
por: Cucurull, Marc, et al.
Publicado: (2022)

An Uncommon Presentation of Mucopolysaccharidosis Type IIIb
por: REZAYI, Alireza, et al.
Publicado: (2019)

To burn-out or not to burn-out: a cross-sectional study in healthcare professionals in Spain during COVID-19 pandemic
por: Torrente, Maria, et al.
Publicado: (2021)

Physiological performance of glyphosate and imazamox mixtures on Amaranthus palmeri sensitive and resistant to glyphosate
por: Fernández-Escalada, Manuel, et al.
Publicado: (2019)

Unravelling the Phytotoxic Effects of Glyphosate on Sensitive and Resistant Amaranthus palmeri Populations by GC–MS and LC–MS Metabolic Profiling
por: Zulet-Gonzalez, Ainhoa, et al.
Publicado: (2023)

Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression
por: Rosell, Rafael, et al.
Publicado: (2009)

A model of mucopolysaccharidosis type IIIB in pigs
por: Yang, Qiang, et al.
Publicado: (2018)

Proteomic Analysis of Mucopolysaccharidosis IIIB Mouse Brain
por: De Pasquale, Valeria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jvqlk6ulatnpnn0n1bv8kl8q60